Vanda Pharmaceuticals Inc VNDA

NAS: VNDA | ISIN: US9216591084   18/06/2026
5,800 USD (-2,68%)
(-2,68%)   18/06/2026

27 mei 2026 · Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis · Persbericht

8 mei 2026 · Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences · Persbericht

6 mei 2026 · Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results · Persbericht

4 mei 2026 · Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years · Persbericht

1 mei 2026 · Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years · Persbericht

29 april 2026 · Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 · Persbericht

29 april 2026 · Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence · Persbericht

22 april 2026 · Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors · Persbericht

9 april 2026 · Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines · Persbericht

8 april 2026 · Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists · Persbericht

19 maart 2026 · Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods · Persbericht

3 maart 2026 · Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years · Persbericht

26 februari 2026 · Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference · Persbericht

25 februari 2026 · Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis · Persbericht

20 februari 2026 · Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation · Persbericht

11 februari 2026 · Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results · Persbericht

5 februari 2026 · Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 · Persbericht

8 januari 2026 · Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder · Persbericht

31 december 2025 · Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness · Persbericht

15 december 2025 · Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis · Persbericht

Mijn selecties